Results 11 to 20 of about 44,855 (147)

CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.

PLoS ONE, 2020
Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13-32% of patients respond to the therapy.
Hiroya Matsuoka, Koji Ando, Emma J Swayze, Elizabeth C Unan, Joseph Mathew, Quingjiang Hu, Yasuo Tsuda, Yuichiro Nakashima, Hiroshi Saeki, Eiji Oki, Ajit K Bharti, Masaki Mori   +11 more
doaj   +1 more source

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

BMC Microbiology, 2023
Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy, Ahmed F. Azmy, Tarek Dishisha, Wafaa R. Mohamed, Kawkab A. Ahmed, Ahmed Hassan, Sahar El Aidy, Ahmed O. El-Gendy   +7 more
doaj   +1 more source

Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan.

PLoS ONE, 2015
Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi, Hye Kyung Hong, Yong Beom Cho, Woo Yong Lee, Hae Yong Yoo   +4 more
doaj   +1 more source

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Frontiers in Oncology, 2021
BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with ...
Jiaojiao Suo, Xiaorong Zhong, Xiaorong Zhong, Ping He, Ping He, Hong Zheng, Hong Zheng, Tinglun Tian, Tinglun Tian, Xi Yan, Xi Yan, Ting Luo, Ting Luo   +12 more
doaj   +1 more source

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

Clinical and Translational Science, 2022
Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity.
Olumide B. Gbolahan, Bert H. O’Neil, Autumn J. McRee, Hanna K. Sanoff, John K. Fallon, Philip C. Smith, Anastasia Ivanova, Dominic T. Moore, Julie Dumond, Gary N. Asher   +9 more
doaj   +1 more source

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer

Oncology and Therapy, 2023
Introduction Liposomal irinotecan promotes controlled sustained release of irinotecan (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement of the relative efficacy/safety ratio of a drug) will be higher for liposomal ...
Sandrine Barbier, Benjamin Beaufils, Ricardo de Miguel, Melissa Reyre, Yannick Le Meitour, Andreanne Lortie, Marc Hillairet de Boisferon, Sophie Chaumeron, Anne Espirito, Lina Fossati, Pauline Lagarde, Stephan Klinz, Arunthathi Thiagalingam, Stéphane Lezmi, Florence Meyer-Losic   +14 more
doaj   +1 more source

Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment

BMC Cancer, 2018
Background The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau, Céline Gongora   +12 more
doaj   +1 more source

Characterization of mucin 2 expression in colorectal cancer with and without chemotherapies, in vivo and in vitro study

Journal of Umm Al-Qura University for Medical Science, 2021
Background: Colorectal cancer (CRC) is the third and second most prevalent cancer affecting males and females, respectively. 5-fluorouracil (5-FU) and irinotecan are the main chemotherapies for CRC.
Hussain Almasmoum
doaj   +1 more source

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications, 2019
Background The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational ...
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang   +21 more
doaj   +1 more source

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Cancer Medicine, 2023
Objective Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan‐associated toxicity.
Kou Kanesada, Ryouichi Tsunedomi, Shoichi Hazama, Hiroyuki Ogihara, Yoshihiko Hamamoto, Yoshitaro Shindo, Hiroto Matsui, Yukio Tokumitsu, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tatsuya Ioka, Hiroaki Nagano   +13 more
doaj   +1 more source